Ocugen, Inc.

NASDAQ:OCGN

Biotechnology

Healthcare
$0.74 +2.46%

+$0.03 today

Market cap
$250.82M
Beta
2.21
P/E (TTM)
-5.6
EPS (TTM)
-$0.22
52W Low $0.90High $2.73

Volume 5.83M

Average 7.51M

OCGN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Ocugen, Inc.NASDAQ: OCGN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q1 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 100.0%, up 0.0 pp year over year. Over 3 fiscal years it narrowed by 54.1 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
45.9%-5.6 pp YoY
LTMMar 2026
100.0%+0.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year-5.6 pp——
3 years-54.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
45.9%
Year-over-year change
-5.6pp

Gross Margin vs competitors

How OCGN compares with its peers on the latest reported figures

  • OCGN's LTM Mar 2026 gross margin of 100.0% is the highest of the 6 companies compared; the peer median is 90.7%.
  • Its year-over-year change of +0.0 pp is the 3rd highest of 5, against a peer median of -0.6 pp.
  • Over three fiscal years its change of -54.1 pp compares with a peer median of -0.9 pp.
OCGN Competitors Peer median
Gross Margin for OCGN and competitors
Company Period LTM level YoY 3-year change
OCGNOcugen, Inc.LTM Mar 2026100.0% +0.0 pp-54.1 pp
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 202699.1% +83.0 pp+37780.7 pp
LCTXLineage Cell Therapeutics, Inc.LTM Mar 202698.0% +0.8 pp-0.9 pp
ADCTADC Therapeutics S.A.LTM Mar 202690.7% -2.0 pp-7.9 pp
ALMSAlumis Inc. Common StockLTM Jun 202688.2% -7.7 pp—
OMEROmeros CorporationLTM Mar 2026-12.4% ——
NGNENeurogene Inc.FY2025— ——
FULCFulcrum Therapeutics, Inc.FY2025— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding OCGN) 90.7%-0.6 pp-0.9 pp

Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue02.49M6.04M4.06M4.41M
Cost of Revenue00704K1.97M2.39M
Gross Profit02.49M5.33M2.09M2.02M
Gross Margin—100.0%88.3%51.5%45.9%
Research & Development35.11M56.16M39.57M32.13M39.75M
Selling, General & Admin22.92M35.4M31.99M26.69M27.58M
Operating Expenses58.03M91.56M70.86M56.84M64.94M
Depreciation & Amortization229K480K704K1.97M2.39M
EBITDA(58.11M)(86.32M)(62.37M)(52.09M)(60.27M)
EBITDA Margin—-3469.6%-1033.4%-1284.5%-1365.7%
Operating Income(58.03M)(89.07M)(65.53M)(54.76M)(62.92M)
Operating Margin—-3580.0%-1085.7%-1350.4%-1425.7%
Interest Income01.4M2.5M1.3M922K
Interest Expense79K0005.19M
Other Income / Expenses(389K)2.27M2.45M703K(4.93M)
Income Before Tax(58.42M)(86.8M)(63.08M)(54.05M)(67.85M)
Pre-Tax Margin—-3488.9%-1045.0%-1333.0%-1537.4%
Income Tax Expense(52K)0000
Net Income(58.37M)(86.8M)(63.08M)(54.05M)(67.85M)
Net Margin—-3488.9%-1045.0%-1333.0%-1537.4%
EPS (Basic)(0.30)(0.40)(0.26)(0.20)(0.23)
EPS (Diluted)(0.30)(0.40)(0.26)(0.20)(0.23)
Weighted Avg Shares195.01M214.6M244.33M271M300.17M
Weighted Avg Shares (Diluted)195.01M214.6M244.33M271M300.17M

Ocugen, Inc.

NASDAQ:OCGN

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.